Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in Clinical RadiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- PET and MRI in cardiac imaging: from validation studies to integrated applications.Eur J Nucl Med Mol Imaging. 2009; 36: S121-S130
- Hybrid PET/MR imaging of the heart: potential, initial experiences, and future prospects.J Nucl Med. 2013; 54: 402-415
- Imaging of the myocardium using (18)F-FDG-PET/MRI.Eur J Radiol. 2016; 85: 1900-1908
- Cardiac PET/MRI-an update.Eur J Hybrid Imaging. 2019; 3: 2
- MR/PET imaging of the cardiovascular system.JACC Cardiovasc Imaging. 2017; 10: 1165-1179
- Molecular imaging in nuclear cardiology: pathways to individual precision medicine.J Nucl Cardiol. 2020; 27: 2195-2201
- Towards better definition, quantification and treatment of fibrosis in heart failure. a scientific roadmap by the committee of translational research of the heart failure association (HFA) of the european society of cardiology.Eur J Heart Fail. 2019; 21: 272-285
- Imaging inflammation in patients and animals: focus on PET imaging the vulnerable plaque.Cells. 2021; 10: 2573
- An overview of PET/MR, focused on clinical applications.Abdom Radiol (NY). 2017; 42: 631-644
- PET/MRI: where might it replace PET/CT?.J Magn Reson Imaging. 2017; 46: 1247-1262
- The role of PET/MR imaging in precision medicine.PET Clin. 2017; 12: 489-501
- Integrated PET/MR.J Magn Reson Imaging. 2014; 39: 243-258
- Combined PET/MR: a technology becomes mature.J Nucl Med. 2015; 56: 165-168
- NEMA NU 2-2012 performance studies for the SiPM-based ToF-PET component of the GE SIGNA PET/MR system.Med Phys. 2016; 43: 2334
- Advances in clinical PET/MRI instrumentation.PET Clin. 2016; 11: 95-103
- Towards quantitative PET/MRI: a review of MR-based attenuation correction techniques.Eur J Nucl Med Mol Imaging. 2009; 36: S93-S104
- Challenges and current methods for attenuation correction in PET/MR.MAGMA. 2013; 26: 81-98
- MRI for attenuation correction in PET: methods and challenges.MAGMA. 2013; 26: 99-113
- Whole-body PET/MRI: the effect of bone attenuation during MR-based attenuation correction in oncology imaging.Eur J Radiol. 2014; 83: 1177-1183
- Whole-body PET/MR imaging: quantitative evaluation of a novel model-based MR attenuation correction method including bone.J Nucl Med. 2015; 56: 1061-1066
- PET/MR imaging of bone lesions--implications for PET quantification from imperfect attenuation correction.Eur J Nucl Med Mol Imaging. 2012; 39: 1154-1160
- 18F-FDG PET/CT and PET/MRI perform equally well in cancer: evidence from studies on more than 2,300 patients.J Nucl Med. 2016; 57: 420-430
- Deep learning MR imaging-based attenuation correction for PET/MR Imaging.Radiology. 2018; 286: 676-684
- Artificial intelligence-based data corrections for attenuation and scatter in position emission tomography and single-photon emission computed tomography.PET Clin. 2021; 16: 543-552
- Deep learning based synthetic-CT generation in radiotherapy and PET: a review.Med Phys. 2021; 48: 6537-6566
- Cardiac and respiratory motion correction for simultaneous cardiac PET/MR.J Nucl Med. 2017; 58: 846-852
- MR-based respiratory and cardiac motion correction for PET imaging.Med Image Anal. 2017; 42: 129-144
- MR-guided motion-corrected PET image reconstruction for cardiac PET-MR.J Nucl Med. 2021; 62: 1768-1774
- Low-dose PET image noise reduction using deep learning: application to cardiac viability FDG imaging in patients with ischemic heart disease.Phys Med Biol. 2021; 66: 054003
- Initial experience with low-dose 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging with deep learning enhancement.J Comput Assist Tomogr. 2021; 45: 637-642
- Machine learning in quantitative PET: a review of attenuation correction and low-count image reconstruction methods.Phys Med. 2020; 76: 294-306
- 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines.Circulation. 2021; 144: e368-e454
- Diagnostic accuracy of stress myocardial perfusion imaging compared to invasive coronary angiography with fractional flow reserve meta-analysis.Circ Cardiovasc Imaging. 2015; 8: e002666
- Quantitative myocardial perfusion evaluation with positron emission tomography and the risk of cardiovascular events in patients with coronary artery disease: a systematic review of prognostic studies.Eur Heart J - Cardiovasc Imaging. 2017; 19: 1179-1187
- Does quantification of myocardial flow reserve using rubidium-82 positron emission tomography facilitate detection of multivessel coronary artery disease?.J Nucl Cardiol. 2012; 19: 670-680
- Comparison of MRI and positron emission tomography for measuring myocardial perfusion reserve in healthy humans.Magn Reson Med. 2006; 55: 772-779
- Quantification of myocardial blood flow with dynamic perfusion 3.0 Tesla MRI: Validation with (15) O-water PET.J Magn Reson Imaging. 2015; 42: 754-762
- Quantification of MRI measured myocardial perfusion reserve in healthy humans: a comparison with positron emission tomography.J Magn Reson Imaging. 2008; 27: 818-824
- Quantification of absolute myocardial perfusion in patients with coronary artery disease: comparison between cardiovascular magnetic resonance and positron emission tomography.J Am Coll Cardiol. 2012; 60: 1546-1555
- Estimating myocardial perfusion from dynamic contrast-enhanced CMR with a model-independent deconvolution method.J Cardiovasc Magn Reson. 2008; 10: 52
- Fully quantitative cardiovascular magnetic resonance myocardial perfusion ready for clinical use: a comparison between cardiovascular magnetic resonance imaging and positron emission tomography.J Cardiovasc Magn Reson. 2017; 19: 78
- Quantification of myocardial perfusion using cardiac magnetic resonance imaging correlates significantly to rubidium-82 positron emission tomography in patients with severe coronary artery disease: a preliminary study.Eur J Radiol. 2014; 83: 1120-1128
- Myocardial perfusion quantification using simultaneously acquired (13) NH(3)-ammonia PET and dynamic contrast-enhanced MRI in patients at rest and stress.Magn Reson Med. 2018; 80: 2641-2654
- Simultaneous (13)N-Ammonia and gadolinium first-pass myocardial perfusion with quantitative hybrid PET-MR imaging: a phantom and clinical feasibility study.Eur J Hybrid Imaging. 2019; 3: 15
- Comparison between quantitative cardiac magnetic resonance perfusion imaging and [(15)O]H(2)O positron emission tomography.Eur J Nucl Med Mol Imaging. 2020; 47: 1688-1697
- Evaluation of quantitative CMR perfusion imaging by comparison with simultaneous (15)O-water-PET.J Nucl Cardiol. 2021; 28: 1252-1266
- Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging.Circulation. 2002; 105: 162-167
- PET/MRI early after myocardial infarction: evaluation of viability with late gadolinium enhancement transmurality vs. 18F-FDG uptake.Eur Heart J Cardiovasc Imaging. 2015; 16: 661-669
- Assessment of myocardial viability in ischemic heart disease by PET/MRI: comparison of left ventricular perfusion, hibernation, and scar burden.Acad Radiol. 2020; 27: 188-197
- Quantifying the area at risk in reperfused ST-segment-elevation myocardial infarction patients using hybrid cardiac positron emission tomography-magnetic resonance imaging.Circ Cardiovasc Imaging. 2016; 9: e003900
- Hybrid PET/MR imaging for the prediction of left ventricular recovery after percutaneous revascularisation of coronary chronic total occlusions.Eur J Nucl Med Mol Imaging. 2020; 47: 3074-3083
- Myocardial viability with chronic total occlusion assessed by hybrid positron emission tomography/magnetic resonance imaging.J Nucl Cardiol. 2021; 28: 2335-2342
- Hybrid positron emission tomography-magnetic resonance of the heart: current state of the art and future applications.Eur Heart J Cardiovasc Imaging. 2018; 19: 962-974
- Integrated cardiovascular assessment of atherosclerosis using PET/MRI.Br J Radiol. 2020; 93: 20190921
- 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial.Lancet. 2014; 383: 705-713
- Vulnerable plaque imaging using (18)F-sodium fluoride positron emission tomography.Br J Radiol. 2020; 93: 20190797
- (18)F-sodium fluoride positron emission tomography for molecular imaging of coronary atherosclerosis based on computed tomography analysis.Atherosclerosis. 2017; 263: 385-392
- Advances in quantitative analysis of (18)F-sodium fluoride coronary imaging.Mol Imaging. 2021; 2021: 8849429
Fiz F, Piccardo A, Morbelli S, Bottoni G, Piana M, Cabria M, Bagnasco M, Sambuceti G. Longitudinal analysis of atherosclerotic plaques evolution: an (18)F-NaF PET/CT study. J Nucl Cardiol. 2021. Epub 2021/02/26. doi: 10.1007/s12350-021-02556-3.
- Hybrid PET/CT and PET/MRI imaging of vulnerable coronary plaque and myocardial scar tissue in acute myocardial infarction.J Nucl Cardiol. 2018; 25: 2001-2011
- Coronary artery PET/MR imaging: feasibility, limitations, and solutions.JACC Cardiovasc Imaging. 2017; 10: 1103-1112
- PET imaging of post-infarct myocardial inflammation.Curr Cardiol Rep. 2021; 23: 99
- Hybrid PET/MR imaging in myocardial inflammation post-myocardial infarction.J Nucl Cardiol. 2020; 27: 2083-2099
- Molecular imaging of myocardial inflammation with positron emission tomography post-ischemia: a determinant of subsequent remodeling or recovery.JACC Cardiovasc Imaging. 2018; 11: 1340-1355
- Prospective evaluation of 18F-fluorodeoxyglucose uptake in postischemic myocardium by simultaneous positron emission tomography/magnetic resonance imaging as a prognostic marker of functional outcome.Circ Cardiovasc Imaging. 2016; 9: e004316
- Quantitative cardiovascular magnetic resonance: extracellular volume, native T1 and 18F-FDG PET/CMR imaging in patients after revascularized myocardial infarction and association with markers of myocardial damage and systemic inflammation.J Cardiovasc Magn Reson. 2018; 20: 33
- Clinical utility and future applications of PET/CT and PET/CMR in cardiology.Diagnostics (Basel). 2016; 6: 32
- Radionuclide image-guided repair of the heart.JACC Cardiovasc Imaging. 2020; 13: 2415-2429
- Molecular imaging of cardiac remodelling after myocardial infarction.Basic Res Cardiol. 2018; 113: 10
- The changing face of nuclear cardiology: guiding cardiovascular care toward molecular medicine.J Nucl Med. 2020; 61: 951-961
- Phase-III clinical trial of fluorine-18 flurpiridaz positron emission tomography for evaluation of coronary artery disease.J Am Coll Cardiol. 2020; 76: 391-401
- Assessing myocardial perfusion in suspected coronary artery disease: rationale and design of the second phase 3, open-label multi-center study of flurpiridaz (F-18) injection for positron emission tomography (PET) imaging.J Nucl Cardiol. 2021; 28: 1105-1116
- Applications of PET-mr imaging in cardiovascular disorders.PET Clin. 2020; 15: 509-520
- Molecular imaging of early αvβ3 integrin expression predicts long-term left-ventricle remodeling after myocardial infarction in rats.J Nucl Med. 2012; 53: 318-323
- Molecular imaging of the chemokine receptor CXCR4 After acute myocardial infarction.JACC Cardiovasc Imaging. 2015; 8: 1417-1426
- Cardiac αVβ3 integrin expression following acute myocardial infarction in humans.Heart. 2017; 103: 607-615
- Radiopharmaceutical tracers for cardiac imaging.J Nucl Cardiol. 2018; 25: 1204-1236
- Measuring cardiac efficiency using PET/MRI.EJNMMI Phys. 2015; 2: A59
- Molecular imaging of fibroblast activity after myocardial infarction using a (68)Ga-labeled fibroblast activation protein inhibitor, FAPI-04.J Nucl Med. 2019; 60: 1743-1749
- Visualization of fibroblast activation after myocardial infarction using 68Ga-FAPI PET.Clin Nucl Med. 2021; 46: 807-813
- Molecular imaging identifies fibroblast activation beyond the infarct region after acute myocardial infarction.J Am Coll Cardiol. 2021; 77: 1835-1837
Notohamiprodjo S, Nekolla SG, Robu S, Villagran Asiares A, Kupatt C, Ibrahim T, Laugwitz K-L, Makowski MR, Schwaiger M, Weber WA, Varasteh Z. Imaging of cardiac fibroblast activation in a patient after acute myocardial infarction using 68Ga-FAPI-04. J Nucl Cardiol. 2021. doi: 10.1007/s12350-021-02603-z.
Xie B, Wang J, Xi XY, Guo X, Chen BX, Li L, Hua C, Zhao S, Su P, Chen M, Yang MF. Fibroblast activation protein imaging in reperfused ST-elevation myocardial infarction: comparison with cardiac magnetic resonance imaging. Eur J Nucl Med Mol Imaging. 2022. Epub 2022/01/06. doi: 10.1007/s00259-021-05674-9.
- Cardiac hybrid imaging: novel tracers for novel targets.J Geriatr Cardiol. 2021; 18: 748-758
- Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis.Circulation. 1978; 58: 1204-1211
- Causes of death in patients with sarcoidosis. a morphologic study of 38 autopsies with clinicopathologic correlations.Arch Pathol Lab Med. 1995; 119: 167-172
- Sarcoidosis-related mortality in the United States from 1988 to 2007.Am J Respir Crit Care Med. 2011; 183: 1524-1530
- Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11).Am J Med. 1977; 63: 86-108
- Japanese guidelines for cardiac sarcoidosis.Ann Nucl Cardiol. 2017; 3: 121-124
- Diagnostic standard and guidelines for sarcoidosis.Jpn J Sarcoidosis Granulomatous Disord. 2007; 27: 89-102
- HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis.Heart Rhythm. 2014; 11: 1305-1323
- Joint SNMMI-ASNC expert consensus document on the role of (18)F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring.J Nucl Cardiol. 2017; 24: 1741-1758
- The role of multimodality imaging in cardiac sarcoidosis.Korean Circ J. 2021; 51: 561-578
- A joint procedural position statement on imaging in cardiac sarcoidosis: from the cardiovascular and inflammation & infection committees of the European association of nuclear medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology.J Nucl Cardiol. 2018; 25: 298-319
- Hybrid cardiac imaging using PET/MRI: a joint position statement by the European Society of Cardiovascular Radiology (ESCR) and the European Association of Nuclear Medicine (EANM).Eur Radiol. 2018; 28: 4086-4101
- Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation (4Is)-related cardiovascular diseases: a joint collaboration of the EACVI and the EANM.Eur J Nucl Med Mol Imaging. 2021; 48: 1016-1039
- T2-weighted short-tau-inversion-recovery imaging reflects disease activity of cardiac sarcoidosis.Open Heart. 2021; 8: e001728
- Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation- (4Is) related cardiovascular diseases: a joint collaboration of the EACVI and the EANM: summary.Eur Heart J Cardiovasc Imaging. 2020; 21: 1320-1330
- 135 novel hybrid positron emission tomography - magnetic resonance (PET-MR) multi-modality inflammatory imaging has improved diagnostic accuracy for detecting cardiac sarcoidosis.Heart. 2014; 100: A80
- Initial experience with simultaneous 18F-FDG PET/MRI in the evaluation of cardiac sarcoidosis and myocarditis.Clin Nucl Med. 2017; 42: e328-e334
- Hybrid magnetic resonance imaging and positron emission tomography with fluorodeoxyglucose to diagnose active cardiac sarcoidosis.JACC Cardiovasc Imaging. 2018; 11: 94-107
- Same day comparison of PET/CT and PET/MR in patients with cardiac sarcoidosis.J Nucl Cardiol. 2020; 27: 2118-2129
- Diagnostic accuracy and prognostic value of simultaneous hybrid 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in cardiac sarcoidosis.Eur Heart J - Cardiovasc Imaging. 2018; 19: 757-767
- Complementary value of cardiac magnetic resonance imaging and positron emission tomography/computed tomography in the assessment of cardiac sarcoidosis.Circ Cardiovasc Imaging. 2018; 11: e007030
- Diagnostic utility of fusion (18)F-fluorodeoxyglucose positron emission tomography/cardiac magnetic resonance imaging in cardiac sarcoidosis.J Nucl Cardiol. 2020; 29: 753-764
- Combined simultaneous FDG-PET/MRI with T1 and T2 mapping as an imaging biomarker for the diagnosis and prognosis of suspected cardiac sarcoidosis.Eur J hybrid Imaging. 2021; 5: 24
- Hybrid cardiac magnetic resonance/fluorodeoxyglucose positron emission tomography to differentiate active from chronic cardiac sarcoidosis.JACC Cardiovasc Imaging. 2021; 15: 445-456
- A joint procedural position statement on imaging in cardiac sarcoidosis: from the cardiovascular and inflammation & infection committees of the european association of nuclear medicine, the european association of cardiovascular imaging, and the american society of nuclear cardiology.Eur Heart J Cardiovasc Imaging. 2017; 18: 1073-1089
- Cardiac MRI and FDG PET in cardiac sarcoidosis: competitors or collaborators?.Radiol Cardiothorac Imaging. 2020; 2: e200347
- Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations.J Am Coll Cardiol. 2018; 72: 3158-3176
- Comparison of original and 2018 Lake Louise criteria for diagnosis of acute myocarditis: results of a validation cohort.Radiol Cardiothorac Imaging. 2019; 1: e190010
- Comprehensive cardiac magnetic resonance imaging in patients with suspected myocarditis: the MyoRacer-trial.J Am Coll Cardiol. 2016; 67: 1800-1811
- Native T1 in discrimination of acute and convalescent stages in patients with clinical diagnosis of myocarditis: a proposed diagnostic algorithm using CMR.JACC Cardiovasc Imaging. 2015; 8: 37-46
- Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2∗ and extracellular volume: a consensus statement by the society for cardiovascular magnetic resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI).J Cardiovasc Magn Reson. 2017; 19: 75
- Feasibility of FDG-PET in myocarditis: comparison to CMR using integrated PET/MRI.J Nucl Cardiol. 2018; 25: 785-794
- Assessment of myocarditis: cardiac MR, PET/CT, or PET/MR?.Curr Cardiol Rep. 2019; 21: 76
- Combined cardiac fluorodeoxyglucose–positron emission tomography/magnetic resonance imaging assessment of myocardial injury in patients who recently recovered from COVID-19.JAMA Cardiol. 2022; 7: 298-308
- Administration of unfractionated heparin with prolonged fasting could reduce physiological 18F-fluorodeoxyglucose uptake in the heart.Acta Radiol. 2016; 57: 661-668
- Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation.J Nucl Cardiol. 2017; 24: 86-99
- Somatostatin receptor based hybrid imaging in sarcoidosis.Eur J Hybrid Imaging. 2017; 1: 7
- PET imaging in cardiac sarcoidosis: a narrative review with focus on novel PET tracers.Pharmaceuticals (Basel). 2021; 14
Park J, Young BD, Miller EJ. Potential novel imaging targets of inflammation in cardiac sarcoidosis. J Nucl Cardiol. 2021. Epub 2021/11/05. doi: 10.1007/s12350-021-02838-w.
- 68Ga-DOTATOC PET for treatment efficacy evaluation of cardiac sarcoidosis.Clin Nucl Med. 2020; 45: e416-e418
- A dual tracer (68)Ga-DOTANOC PET/CT and (18)F-FDG PET/CT pilot study for detection of cardiac sarcoidosis.EJNMMI Res. 2016; 6: 52
- Comparison of (68)Ga-DOTANOC PET/CT with cardiac MRI in patients with clinical suspicion of cardiac sarcoidosis.Ann Nucl Med. 2021; 35: 1058-1065
- Detection of atherosclerotic inflammation by (68)Ga-DOTATATE PET compared to [(18)F]FDG PET imaging.J Am Coll Cardiol. 2017; 69: 1774-1791
- Novel positron emission tomography tracers for imaging vascular inflammation.Curr Cardiol Rep. 2020; 22: 119
- FLT-PET for the assessment of systemic sarcoidosis including cardiac and CNS involvement: a prospective study with comparison to FDG-PET.EJNMMI Res. 2020; 10: 154
- Imaging the cytokine receptor CXCR4 in atherosclerotic plaques with the radiotracer (68)Ga-pentixafor for PET.J Nucl Med. 2017; 58: 499-506
- Upregulated myocardial CXCR4-expression after myocardial infarction assessed by simultaneous GA-68 pentixafor PET/MRI.J Nucl Cardiol. 2016; 23: 131-133
- Imaging of C-X-C motif chemokine receptor CXCR4 expression after myocardial infarction with [(68)Ga]Pentixafor-PET/CT in correlation with cardiac MRI.JACC Cardiovasc Imaging. 2018; 11: 1541-1543
- Molecular imaging visualizes recruitment of inflammatory monocytes and macrophages to the injured heart.Circ Res. 2019; 124: 881-890
- ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging.J Nucl Cardiol. 2019; 26: 2065-2123
- Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis.Circulation. 2015; 132: 1570-1579
- 18)F-Sodium fluoride PET/MR for the assessment of cardiac amyloidosis.J Am Coll Cardiol. 2016; 68: 2712-2714
- 18)F-sodium fluoride PET/MRI myocardial imaging in patients with suspected cardiac amyloidosis.J Nucl Cardiol. 2021; 28: 1586-1595
- 18F-fluoride PET/MR in cardiac amyloid: a comparison study with aortic stenosis and age- and sex-matched controls.J Nucl Cardiol. 2020; 29: 741-749
- Editorial: 18F-Fluoride PET/MR in cardiac amyloid; simple addition versus synergy?.J Nucl Cardiol. 2020; 29: 750-752
- In Vivo visualization of amyloid deposits in the heart with 11C-PIB and PET.J Nucl Med. 2013; 54: 213-220
- Imaging cardiac amyloidosis: a pilot study using 1⁸F-florbetapir positron emission tomography.Eur J Nucl Med Mol Imaging. 2014; 41: 1652-1662
- [18F]-florbetaben PET/CT for differential diagnosis among cardiac immunoglobulin light chain, transthyretin amyloidosis, and mimicking conditions.JACC Cardiovasc Imaging. 2020; 14: 246-255
- Pilot study of F18-florbetapir in the early evaluation of cardiac amyloidosis.Front Cardiovasc Med. 2021; 8: 693194
- Improved quantification of cardiac amyloid burden in systemic light chain amyloidosis: redefining early disease?.JACC Cardiovasc Imaging. 2020; 13: 1325-1336
- 11C-Pittsburgh B PET imaging in cardiac amyloidosis.JACC Cardiovasc Imaging. 2015; 8: 50-59
- Diagnostic accuracy of [(11)C]PIB positron emission tomography for detection of cardiac amyloidosis.JACC Cardiovasc Imaging. 2020; 13: 1337-1347
- 18F-flutemetamol positron emission tomography in cardiac amyloidosis.J Nucl Cardiol. 2020; 29: 779-789
- Advances in PET-based cardiac amyloid radiotracers.Curr Cardiol Rep. 2020; 22: 40
- Diagnostic performance of CMR, SPECT, and PET imaging for the detection of cardiac amyloidosis: a meta-analysis.BMC Cardiovasc Disord. 2021; 21: 482
- Positron emission tomography for cardiac amyloidosis: timing matters!.J Nucl Cardiol. 2021; 29: 790-797
- First experience of simultaneous PET/MRI for the early detection of cardiac involvement in patients with Anderson-Fabry disease.Eur J Nucl Med Mol Imaging. 2015; 42: 1025-1031
- Role of serial cardiac (18)F-FDG PET-MRI in Anderson-Fabry disease: a pilot study.Insights Imaging. 2021; 12: 124
- Evaluation of myocardial glucose metabolism in hypertrophic cardiomyopathy using 18F-fluorodeoxyglucose positron emission tomography.PLoS One. 2017; 12: e0188479
- Myocardial fibrosis in hypertrophic cardiomyopathy demonstrated by integrated cardiac F-18 FDG PET/MR.Nucl Med Mol Imaging. 2013; 47: 196-200
- Cardiac imaging with 18F-fluorodeoxyglucose PET/MRI in hypertrophic cardiomyopathy.J Nucl Cardiol. 2017; 24: 1827-1828
- Positron emission tomography/MRI for cardiac diseases assessment.Br J Radiol. 2020; 93: 20190836
- Clinical use of cardiac PET/MRI: current state-of-the-art and potential future applications.Jpn J Radiol. 2018; 36: 313-323
- PET tracers for imaging cardiac function in cardio-oncology.Curr Cardiol Rep. 2022; 24: 247-260
- Relationship between cardiac fibroblast activation protein activity by positron emission tomography and cardiovascular disease.Circ Cardiovasc Imaging. 2020; 13: e010628
- Cardiac MRI for the evaluation of oncologic cardiotoxicity.J Nucl Cardiol. 2018; 25: 2148-2158
- The use of cardiovascular magnetic resonance as an early non-invasive biomarker for cardiotoxicity in cardio-oncology.Cardiovasc Diagn Ther. 2020; 10: 610-624
- Role of cardiovascular magnetic resonance imaging in cardio-oncology.Eur Heart J - Cardiovasc Imaging. 2021; 22: 383-396
Aghayev A, Cheezum MK, Steigner ML, Mousavi N, Padera R, Barac A, Kwong RY, Di Carli MF, Blankstein R. Multimodality imaging to distinguish between benign and malignant cardiac masses. J Nucl Cardiol. 2021. Epub 2021/09/04. doi: 10.1007/s12350-021-02790-9.
- Integrated 18F-FDG PET/MR imaging in the assessment of cardiac masses: a pilot study.J Nucl Med. 2015; 56: 255-260
- PET-MR imaging in evaluation of cardiac and paracardiac masses with histopathologic correlation.JACC Cardiovasc Imaging. 2016; 9: 82-85
Yaddanapudi K, Brunken R, Tan CD, Rodriguez ER, Bolen MA. PET-MR Imaging in Evaluation of Cardiac and Paracardiac Masses With Histopathologic Correlation. JACC Cardiovasc Imaging. 2016;9(1):82-5. doi: https://doi.org/10.1016/j.jcmg.2015.04.028.
- Molecular positron emission tomography in cardiac ischemia/reperfusion.Circ Res. 2019; 124: 827-829
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
